Results 261 to 270 of about 20,079 (290)
Some of the next articles are maybe not open access.

Cytisine Versus Varenicline for Smoking Cessation in a Primary Care Setting: A Randomized Non-inferiority Trial.

Nicotine & Tobacco Research, 2023
INTRODUCTION A smoking-cessation program was implemented as a randomized non-inferiority trial in primary care practices in Croatia and Slovenia to investigate whether a standard 4-week treatment with cytisine was at least as effective and feasible as a ...
T. Oreskovic   +6 more
semanticscholar   +1 more source

Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis

Journal of addiction medicine, 2023
Objective An overview, meta-analysis, and trial sequential analysis were conducted to evaluate the efficacy and safety of varenicline for smoking cessation.
X. Shang   +7 more
semanticscholar   +1 more source

Pharmacokinetic comparisons of two different varenicline formulations in humans: Varenicline tartrate versus varenicline oxalate

Int. Journal of Clinical Pharmacology and Therapeutics, 2020
Varenicline is an effective drug for smoking cessation. The aim of the present study was to compare the pharmacokinetics and safety profiles of two different varenicline formulations (varenicline tartrate (reference) and varenicline oxalate (test)), each containing 1 mg varenicline base in humans.A randomized, open-label, two-sequence, two-period ...
Jin-Woo Park   +4 more
openaire   +3 more sources

Intranasal Varenicline: Review of a Novel Formulation for the Treatment of Dry Eye Disease

Journal of pharmacy and practice, 2022
Objective: To examine the literature pertaining to safety and efficacy of intranasal (IN) varenicline for the treatment of dry eye disease (DED). Data Sources: A literature search of PubMed was performed (1985 to January 2022) using the following search ...
K. Zitko, Lauren Ladd, T. Dougherty
semanticscholar   +1 more source

Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.

Alcoholism: Clinical and Experimental Research, 2022
BACKGROUND The U.S. Food and Drug Administration identifies abstinence and the absence of heavy drinking days as outcomes for pharmacotherapy trials for alcohol use disorder (AUD).
Steven J. Nieto   +4 more
semanticscholar   +1 more source

Varenicline

2012
Varenicline is a novel agent that is centrally acting partial nicotinic acetylcholine receptor antagonist. It has both agonistic and antagonistic properties that together are believed to account for reduction of craving and withdrawal as well as blocking the rewarding effects of smoking. Its targeted mechanism of action,better efficacy and tolerability
Mohammed Gabr Kassem   +1 more
openaire   +3 more sources

Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial.

JAMA Internal Medicine
Importance Little is known about the relative effectiveness of nicotine-containing electronic cigarettes (ECs) compared with varenicline as smoking cessation aids. Objective To determine the relative effectiveness of ECs in smoking cessation. Design,
Anna Tuisku   +3 more
semanticscholar   +1 more source

Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA)
Importance Most people who smoke do not quit on their initial attempt. Objective To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT). Design, Setting,
P. Cinciripini   +11 more
semanticscholar   +1 more source

Effectiveness of Varenicline versus Combination Nicotine Replacement Therapy for Smoking Cessation: One Year Outcomes in a Smoking Cessation Clinic in Taiwan.

Nicotine & Tobacco Research, 2021
INTRODUCTION Varenicline and combination nicotine replacement treatment (cNRT) have been recommended as the most effective pharmacotherapies, with equal abstinence rate for smoking cessation in a network meta-analysis of randomized trials, but data from ...
K. Hsueh, P. Tang, H. McRobbie
semanticscholar   +1 more source

Varenicline for the Treatment of Cocaine Dependence

Journal of Addiction Medicine, 2021
Objectives: Varenicline is a partial agonist at the α2β4 and α6β2 nAChR receptors and a full agonist at α7 receptors. Both α7 and α6β2 receptors are implicated in the neural reward circuitry activated by cocaine use. A preliminary clinical trial suggested that varenicline treatment reduced cocaine use.
Mila Tamminga   +6 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy